Last updated: August 16, 2026
Zyrtec-D 12 Hour is an over-the-counter extended-release combination of cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg. Its commercial position is mature rather than exclusivity-driven. The product benefits from strong brand recognition, seasonal demand, and a differentiated combination of antihistamine and nasal decongestant, but faces generic substitution, pseudoephedrine access restrictions, retailer competition, and limited public financial disclosure.
The product has no meaningful current patent barrier to generic competition. Its regulatory protection comes from the OTC framework and brand equity, not an active Orange Book estate. Kenvue, which owns the Zyrtec brand following Johnson & Johnson's consumer-health separation, reports financial results at portfolio and segment levels rather than for Zyrtec-D 12 Hour specifically. Product-level revenue, margin, and unit data are not publicly reported.
What is Zyrtec-D 12 Hour and how does it work?
Zyrtec-D 12 Hour combines two active ingredients in one extended-release tablet:
| Component |
Amount per tablet |
Function |
| Cetirizine hydrochloride |
5 mg |
H1 antihistamine for allergic symptoms |
| Pseudoephedrine hydrochloride |
120 mg |
Nasal decongestant |
| Dosing interval |
Every 12 hours |
Two tablets maximum per 24 hours |
The product is indicated for temporary relief of nasal and sinus congestion, sinus pressure, sneezing, runny nose, itchy nose or throat, and itchy or watery eyes associated with allergies or the common cold. The extended-release design separates the product from ordinary cetirizine products such as Zyrtec 24 Hour, which do not contain pseudoephedrine.
Pseudoephedrine creates the product's principal commercial and regulatory distinction. It is sold behind the pharmacy counter in the United States because of federal restrictions intended to limit diversion for illicit methamphetamine production. Purchasers generally must show identification, and federal purchase limits apply under the Combat Methamphetamine Epidemic Act of 2005.[1]
Who owns Zyrtec-D 12 Hour?
Kenvue owns and markets the Zyrtec consumer-health brand in the United States. Kenvue became an independent public company in 2023 after Johnson & Johnson separated its consumer-health business.[2]
The ownership chain is commercially important:
| Period |
Brand owner or operating structure |
| Before 2023 |
Johnson & Johnson consumer-health business |
| From 2023 |
Kenvue Inc. |
| Product category |
Self-care, allergy and respiratory health |
| U.S. sales channel |
Pharmacy counter, mass retail, grocery, club, e-commerce and other OTC channels |
The underlying active ingredients are generic chemical substances. Kenvue's economic assets are the Zyrtec trademark, product formulation and manufacturing or supply-chain capabilities, retail distribution, consumer awareness, and marketing position.
What is the market position of Zyrtec-D 12 Hour?
Zyrtec-D 12 Hour competes in the U.S. oral allergy and nasal-decongestant market. Its closest branded competitors include Claritin-D 12 Hour and Allegra-D 12 Hour. Generic cetirizine-pseudoephedrine extended-release products compete primarily on price and pharmacy availability.
| Product |
Antihistamine |
Decongestant |
Typical duration |
Principal commercial distinction |
| Zyrtec-D 12 Hour |
Cetirizine |
Pseudoephedrine |
12 hours |
Strong Zyrtec allergy brand |
| Claritin-D 12 Hour |
Loratadine |
Pseudoephedrine |
12 hours |
Strong Claritin brand |
| Allegra-D 12 Hour |
Fexofenadine |
Pseudoephedrine |
12 hours |
Allegra non-sedating positioning |
| Generic cetirizine-pseudoephedrine ER |
Cetirizine |
Pseudoephedrine |
12 hours |
Lower price |
| Zyrtec 24 Hour |
Cetirizine |
None |
24 hours |
Allergy relief without decongestant |
The combination category is narrower than the overall antihistamine market because pseudoephedrine is subject to purchase restrictions and can produce cardiovascular or central nervous system side effects. That restriction reduces impulse purchases and limits shelf visibility. It also creates pharmacy-counter friction that ordinary cetirizine, loratadine, and fexofenadine products avoid.
Zyrtec-D remains commercially relevant when consumers prioritize congestion relief over once-daily dosing or want one product for both allergy symptoms and nasal obstruction.
How does Zyrtec-D 12 Hour generate revenue?
Zyrtec-D 12 Hour generates revenue through retail sell-in, pharmacy-counter sales, direct retail sales and e-commerce distribution. The product is typically sold in small-count packages, which supports higher price points per dose than large-count ordinary antihistamine products.
The main revenue drivers are:
- Seasonal allergy intensity, especially during spring and early summer.
- Cold and upper-respiratory illness activity.
- Retail pricing and promotional placement.
- Consumer willingness to pay for a branded combination product.
- Availability of the generic equivalent.
- Pharmacy-counter inventory and purchase restrictions.
- Distribution through mass retailers, grocery chains, pharmacies and online sellers.
Demand is seasonal, but the product also has a cold-relief use case that can extend sales outside peak pollen periods. Severe allergy seasons can increase category demand, while mild seasons can reduce unit movement. Weather, pollen counts, respiratory-virus activity and regional demographics affect the sales pattern.
The principal financial limitation is lack of public product-level reporting. Kenvue reports consolidated results and category or segment information, but does not separately disclose Zyrtec-D 12 Hour revenue, gross margin, operating profit, market share or unit volume in its public filings.[2] The product should therefore be analyzed as part of Kenvue's broader self-care and allergy portfolio rather than as a separately valued public reporting unit.
What is the financial trajectory for Zyrtec-D 12 Hour?
The financial trajectory is likely mature and cash-generative, with limited volume growth and continuing price and mix management. The product's future economics depend more on brand retention, retail execution and manufacturing efficiency than on new clinical development.
Historical trajectory
Zyrtec moved from prescription status to OTC status in the United States in 2007. The switch expanded consumer access and shifted the product's commercial model from prescription reimbursement to retail brand competition.[3] The Zyrtec-D combination gained access to the broader OTC allergy market while retaining pseudoephedrine's pharmacy-counter controls.
The product has since operated in a post-exclusivity environment. Generic cetirizine and pseudoephedrine products can compete without replicating Kenvue's advertising investment or brand identity.
Current trajectory
The likely current profile has four characteristics:
| Financial factor |
Effect on Zyrtec-D 12 Hour |
| Brand pricing |
Supports revenue per package above many generics |
| Generic competition |
Limits long-term unit and price growth |
| Seasonal demand |
Produces quarterly volatility |
| OTC operating model |
Avoids prescription-reimbursement exposure but increases retail competition |
Kenvue's wider business has faced the same pressures affecting large OTC portfolios: retailer bargaining power, inflation in input costs, consumer trade-down, promotional activity and shifting channel mix. Zyrtec-D has a relatively defensible brand position but is not insulated from these forces.
Revenue exposure
Zyrtec-D 12 Hour is unlikely to represent a material share of Kenvue's consolidated revenue by itself. Kenvue's portfolio includes much larger brands and product categories, including Tylenol, Neutrogena, Listerine, Aveeno and Motrin. The product's strategic value is its contribution to the allergy franchise and its ability to retain consumers who need congestion relief.
A sharp decline in Zyrtec-D sales would probably have a limited effect on Kenvue's consolidated financial statements. A broader decline across the Zyrtec franchise, however, would be more relevant to the company's self-care performance.
What patents protect Zyrtec-D 12 Hour?
No active product-specific patent estate is central to the current commercial position of Zyrtec-D 12 Hour. The product is an OTC drug containing long-established active ingredients, and its core commercial protection does not depend on patent exclusivity.
The relevant protection categories are:
| Protection type |
Current importance |
| Active-ingredient patents |
None of practical commercial significance |
| Original formulation patents |
Historical relevance; not a current market barrier |
| Trademark protection |
High for the Zyrtec name and trade dress |
| OTC monograph compliance |
Core regulatory pathway |
| Manufacturing know-how |
Possible operational advantage, but not a generic barrier |
| Retail distribution |
Important commercial asset |
| Advertising and consumer recognition |
Important brand defense |
Zyrtec-D 12 Hour is not generally analyzed through the same Orange Book framework as a prescription product. FDA's Orange Book primarily lists approved prescription drug products and related patent and exclusivity information. OTC products marketed under an applicable monograph typically do not receive an Orange Book patent listing comparable to a new prescription drug.[4]
When does Zyrtec-D 12 Hour lose exclusivity?
Zyrtec-D 12 Hour has already lost any meaningful market exclusivity based on active-ingredient or core product patents. The 2007 OTC switch also means the product's primary commercial life has been post-prescription and post-launch exclusivity.
The current protection model is:
- No effective new-drug exclusivity period.
- No commercially significant active patent term.
- No expected patent-based generic launch date.
- Ongoing trademark protection for "Zyrtec."
- Continued market access under the OTC regulatory framework.
Trademark protection does not prevent competitors from selling cetirizine-pseudoephedrine extended-release products under different names. It protects the Zyrtec brand identifier and related branding elements.
Are there Paragraph IV challenges against Zyrtec-D 12 Hour?
Paragraph IV litigation is not the principal generic-entry mechanism for Zyrtec-D 12 Hour. Paragraph IV certifications apply to abbreviated new drug applications that challenge listed patents for approved prescription or other Orange Book-listed products. A monograph-based OTC product generally does not create the same patent-litigation pathway.
Generic manufacturers can market compliant cetirizine-pseudoephedrine products without waiting for a branded prescription product's patent term to expire, subject to FDA requirements, formulation compliance and applicable regulatory obligations. The competitive threat is therefore continuous rather than concentrated around one Paragraph IV launch event.
What FDA regulatory status applies to Zyrtec-D 12 Hour?
Zyrtec-D 12 Hour is an OTC drug regulated under FDA's nonprescription allergy and nasal-decongestant framework. Cetirizine is covered by the OTC antihistamine monograph framework, while pseudoephedrine is covered by the OTC nasal-decongestant framework, subject to product labeling and dosing conditions.[5]
The product must comply with requirements covering:
- Active ingredients and permitted concentrations.
- Extended-release dosage design.
- Indications and warnings.
- Directions and age restrictions.
- Contraindications and drug-interaction warnings.
- Packaging and labeling.
- Pseudoephedrine sale and recordkeeping controls.
Because pseudoephedrine can elevate blood pressure or cause stimulation, labeling addresses hypertension, heart disease, thyroid disease, diabetes, glaucoma, prostate or urinary-retention conditions, and use with monoamine oxidase inhibitors.
What formulations are protected by Zyrtec-D 12 Hour?
The commercial formulation is an extended-release tablet containing cetirizine and pseudoephedrine. The formulation's commercial value lies in combining the two ingredients and releasing pseudoephedrine over approximately 12 hours.
The formulation is not protected by a current exclusivity barrier that prevents generic competition. Generic manufacturers may compete with equivalent or sufficiently comparable extended-release products under applicable FDA requirements. Manufacturing complexity may create quality-control and supply-chain hurdles, but those hurdles are weaker than a live formulation patent.
Potential manufacturing risk areas include:
- Consistent extended-release performance.
- Uniform distribution of active ingredients.
- Tablet compression and coating.
- Stability and packaging.
- Pseudoephedrine inventory controls.
- FDA compliance for OTC labeling and quality systems.
These factors can affect the number of reliable suppliers, but they do not create durable brand-level exclusivity.
How strong is the Zyrtec-D 12 Hour patent estate?
The patent estate is weak as a current barrier to entry and strong only in the narrow sense that the product retains a recognizable trademark and established manufacturing profile.
| Estate characteristic |
Assessment |
| Patent blocking power |
Low |
| Orange Book relevance |
Limited or none |
| Trademark value |
High |
| Formulation differentiation |
Moderate |
| Generic substitution risk |
High |
| Manufacturing barrier |
Low to moderate |
| Regulatory complexity |
Moderate because of pseudoephedrine controls |
The product's moat is commercial rather than legal. Generic products can undercut price, while Kenvue relies on brand trust, advertising, retailer relationships and consumer familiarity.
Which companies are challenging Zyrtec-D 12 Hour?
Competition comes from both branded and generic manufacturers. The principal branded competitors are Bayer's Claritin-D franchise and Opella's Allegra-D franchise, subject to the applicable ownership and marketing arrangements in each market. Generic competition comes from manufacturers and distributors selling cetirizine-pseudoephedrine extended-release tablets, including products supplied through major pharmacy and retail channels.
The competitive landscape also includes substitution away from combination products:
- Ordinary cetirizine for allergy symptoms.
- Loratadine or fexofenadine for nonprescription antihistamine use.
- Phenylephrine-containing products, although FDA has proposed removing oral phenylephrine as an effective OTC nasal-decongestant active ingredient after concluding that available data do not support effectiveness at the labeled dose.[6]
- Intranasal corticosteroids such as fluticasone.
- Saline and non-drug nasal products.
The FDA's position on oral phenylephrine may improve the relative position of pseudoephedrine-based products for consumers seeking oral congestion relief, but pharmacy-counter restrictions limit the size of that opportunity.
What generic entry risks exist for Zyrtec-D 12 Hour?
Generic entry risk is permanent and structural. The principal risks are lower prices, retailer substitution, private-label expansion and reduced consumer loyalty when the branded product is unavailable.
Generic launch scenarios are unlikely to involve a single high-impact patent event. More likely outcomes are:
- Gradual share erosion as retailers promote lower-cost equivalents.
- Stable branded demand among consumers who request Zyrtec specifically.
- Increased price competition during peak allergy seasons.
- Greater online substitution where consumers compare active ingredients.
- Temporary supply disruption if pseudoephedrine controls constrain inventory.
The brand can preserve a premium if consumers associate Zyrtec with reliable allergy relief and if retailers continue to stock the product prominently at pharmacy counters.
What licensing deals and litigation affect Zyrtec-D 12 Hour?
No major current licensing transaction, settlement agreement or patent litigation is publicly associated with Zyrtec-D 12 Hour as a standalone product. The 2023 Johnson & Johnson consumer-health separation transferred the brand portfolio to Kenvue but was a corporate separation, not a product-specific license or generic settlement.[2]
There is no known commercial significance from a current Paragraph IV settlement, authorized-generic arrangement or biosimilar dispute. Biosimilar risk is not applicable because Zyrtec-D 12 Hour is a small-molecule OTC drug, not a biologic.
How does Zyrtec-D 12 Hour compare with Claritin-D and Allegra-D?
Zyrtec-D's main differentiation is cetirizine's established consumer position in allergy relief combined with pseudoephedrine's decongestant effect. Claritin-D competes through loratadine and the Claritin franchise, while Allegra-D relies on fexofenadine and Allegra's non-sedating brand positioning.
| Attribute |
Zyrtec-D 12 Hour |
Claritin-D 12 Hour |
Allegra-D 12 Hour |
| Antihistamine |
Cetirizine |
Loratadine |
Fexofenadine |
| Decongestant |
Pseudoephedrine |
Pseudoephedrine |
Pseudoephedrine |
| Dosage interval |
12 hours |
12 hours |
12 hours |
| Brand strength |
High |
High |
High |
| Patent moat |
Low |
Low |
Low |
| Pharmacy-counter exposure |
Yes |
Yes |
Yes |
| Main advantage |
Zyrtec allergy franchise |
Claritin franchise |
Allegra non-sedating positioning |
| Generic threat |
High |
High |
High |
What is the investment outlook for Zyrtec-D 12 Hour?
Zyrtec-D 12 Hour is a mature OTC cash-flow product, not a pipeline or exclusivity asset. Its investment relevance lies in portfolio durability, pricing discipline and brand retention.
Positive factors include established consumer awareness, recurring allergy demand, the absence of prescription reimbursement risk and the continued need for an effective oral decongestant. Negative factors include generic substitution, pseudoephedrine purchasing friction, limited product-level growth and a lack of patent protection.
The most likely financial path is stable-to-declining unit demand offset partly by pricing, product mix, seasonal strength and distribution. The product can remain profitable without delivering material growth. Its value to Kenvue is likely greater as part of the Zyrtec franchise than as an isolated product.
Key Takeaways
- Zyrtec-D 12 Hour contains cetirizine 5 mg and pseudoephedrine 120 mg in an extended-release 12-hour tablet.
- Kenvue owns the Zyrtec brand after Johnson & Johnson's 2023 consumer-health separation.
- Product-level revenue and profit are not separately disclosed by Kenvue.
- The product has no meaningful current patent exclusivity or practical Orange Book moat.
- Paragraph IV litigation and biosimilar risk are not central to the product's competitive outlook.
- Generic entry is continuous and price-based rather than tied to a single patent expiry.
- The strongest assets are the Zyrtec trademark, consumer recognition, retail distribution and formulation know-how.
- Financial performance is mature, seasonal and likely more dependent on pricing and brand retention than volume growth.
- Pseudoephedrine controls reduce convenience but preserve differentiation versus ordinary antihistamine products.
- The product's principal risks are generic substitution, retailer private labels, pharmacy-counter restrictions and consumer migration to non-decongestant alternatives.
FAQs About Zyrtec-D 12 Hour
Is Zyrtec-D 12 Hour prescription-only?
No. It is an OTC product, but pseudoephedrine sales are controlled and generally require pharmacy-counter purchase and purchaser identification.
Does Zyrtec-D 12 Hour have a generic equivalent?
Yes. Generic cetirizine-pseudoephedrine extended-release products compete with the branded product, subject to FDA requirements and pharmacy-counter controls.
Is Zyrtec-D 12 Hour listed in the Orange Book?
It is not generally treated like an Orange Book-listed prescription product with a branded patent-exclusivity schedule. Its market position is primarily based on OTC compliance and trademark protection.
Can Zyrtec-D 12 Hour be sold through ordinary retail shelves?
The pseudoephedrine component generally requires pharmacy-counter handling in the United States. Retail practices vary, but the product is commonly kept behind the counter or in a controlled-access area.
Does Zyrtec-D 12 Hour have biosimilar competition?
No. Biosimilar rules apply to biologic products. Zyrtec-D 12 Hour is a small-molecule OTC combination drug and faces ordinary generic competition instead.
References
- U.S. Drug Enforcement Administration. (2024). Combat methamphetamine epidemic act of 2005 and pseudoephedrine retail sales requirements. https://www.deadiversion.usdoj.gov
- Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. https://investors.kenvue.com
- U.S. Food and Drug Administration. (2007). FDA approves over-the-counter Zyrtec for allergy relief. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
- U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2023). FDA proposes ending use of oral phenylephrine as an over-the-counter nasal decongestant. https://www.fda.gov
